StockMarketWire.com - HSBC today reaffirms its buy investment rating on Dechra Pharmaceuticals PLC [LON:DPH] and cut its price target to 2700p (from 2770p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk